Multidisciplinary Approaches to Atopic Dermatitis Management and Referrals
January 27th 2025Panelists discuss the diagnosis and referral process for patients with pediatric atopic dermatitis (AD) from both the dermatologist and allergy perspectives, including when a child should be referred to a dermatologist and the importance of a multidisciplinary approach to care for optimizing AD management, with insights on the roles each team member plays in patient care.
Exploring the Pediatric Patient and Caregiver Journey
January 27th 2025Panelists discuss the patient journey for patients with pediatric atopic dermatitis (AD) and their caregivers, from initial presentation through to diagnosis, emphasizing the challenges and emotional aspects that families experience throughout the process.
Considerations for Diagnosing Atopic Dermatitis and Assessing Severity
January 24th 2025Panelists discuss the diagnostic criteria for atopic dermatitis (AD), highlighting challenges in diagnosis due to the disease’s heterogeneity across factors like age, skin color, and other variables, and explore how this complexity can lead to misdiagnosis or late diagnosis; they also share tips for diagnosing AD, determining disease severity, and incorporating patient-reported outcomes into severity assessments, while examining how advances in treatment and understanding have shaped current perspectives on AD severity.
Overview of Atopic Dermatitis Pathophysiology and Atopic March in Children
January 24th 2025Panelists discuss the pathophysiology of atopic dermatitis (AD), focusing on the role of type 2 inflammation, and explore how AD can serve as an entry point to the atopic march in children, leading to other allergic diseases such as food allergies, asthma, and allergic rhinitis, including early indicators that may predict future comorbidities.
Lawrence Eichenfield, MD, talks tapinarof cream, 1%, nemolizumab FDA approvals for atopic dermatitis
December 20th 2024"Tapinarof comes in with that mixture of the short-term studies and longer-term studies intermittently, giving us a nice, effective alternative non-steroid for eczema across the ages."